Archive for the
‘Allgemein’ Category

Ghent, Belgium – June 28, 2022 – Confo Therapeutics announced today that it has been awarded a EUR 1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The award further validates and supports Confo’s leadership in the discovery of novel GPCR (G protein-coupled receptor) drug candidates using its proprietary universal ConfoBody® technology, specifically for the […]

28. June 2022

|

by: confo

|

Categories: 2022, Allgemein

Ghent, Belgium, December 15, 2021 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it has extended its patent estate with four key US and EU patents granted as part of the company’s foundational “Steyaert patents”. The newly added patents (US-11,162,953, US-11,162,954, EP 3557254 and EP […]

15. December 2021

|

by: confo

|

Categories: 2021, Allgemein

— Confo will work together with Regeneron to apply its GPCR drug discovery platform to enable functional antibody discovery — Ghent, Belgium – November 30, 2021 – Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective VHH antibodies – ConfoBodies® […]

30. November 2021

|

by: confo

|

Categories: 2021, Allgemein, Press Releases

Confo Therapeutics Establishes Medical Advisory Board Ghent, Belgium – June 10, 2021 – Confo Therapeutics today announced the establishment of its Medical Advisory Board (MAB). The MAB will provide external review and strategic advice for the company’s clinical development program including the future direction of CFTX-1554, Confo’s lead pre-clinical candidate in neuropathic pain. The international […]

10. June 2021

|

by: confo

|

Categories: 2021, Allgemein, Press Releases

Confo Therapeutics Awarded EUR 1M VLAIO Grant for Pre-Clinical Development of CFTX-1554, an AT2R Modulator for the Treatment of Neuropathic Pain Ghent, Belgium – March 30, 2021 – Confo Therapeutics announced today that it has been awarded a EUR 1 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will support the pre-clinical development […]

30. March 2021

|

by: confo

|

Categories: 2021, Allgemein, Press Releases

Confo Therapeutics Announces Selection of First Product Candidate and Initiation of Pre-Clinical Development Ghent, Belgium – October 15, 2020 – Confo Therapeutics today announced the selection of its first preclinical drug candidate, CFTX-1554, a compound designed to address peripheral neuropathic pain with the potential to address additional pain indications. Confo has applied its proprietary, fragment-based […]

15. October 2020

|

by: confo

|

Categories: Allgemein, 2020, Press Releases

Confo Therapeutics Expands Board with Appointment of Rob Scott as Independent Director Ghent, Belgium – June 10, 2020 – Confo Therapeutics today announced the addition of a new member to its Board of Directors with the appointment of Rob Scott, MD, as an Independent Director. Dr. Scott’s career spans 30 years of drug discovery and […]

10. June 2020

|

by: ante

|

Categories: Allgemein, 2020, Press Releases

Confo Therapeutics Appoints Paolo Vicini as Chief Development Officer –New management role underscores Company’s commitment to establishing and advancing its proprietary pipeline of GPCR modulating drug candidates– Ghent, Belgium – June 3, 2020 – Confo Therapeutics today announced the appointment of Paolo Vicini, PhD, MBA, in the newly-created position of Chief Development Officer (CDO) effective […]

3. June 2020

|

by: ante

|

Categories: Allgemein, 2020, Press Releases

Confo Therapeutics to present at Cowen 40th Annual Health Care Conference Ghent, Belgium, 27 February 2020 – Confo Therapeutics, a pioneering biopharma company, today announces that Cedric Ververken, CEO, will present at the Cowen 40th Annual Health Care Conference on Tuesday, March 3, 2020 at 3:00 p.m. ET in Boston, MA. Confo Therapeutics is also […]

27. February 2020

|

by: confo

|

Categories: Allgemein, 2020, Press Releases

Confo Therapeutics reports grant of two key patents for ConfoBodies™ Ghent, Belgium, 2 December 2019 – Confo Therapeutics, a pioneering biopharma company, today announces that it has been granted two key ConfoBody™ patents derived from the patent estate known as the “Steyaert patents”. The Steyaert patents – named after Prof. Jan Steyaert (VIB-VUB), their first-named […]

2. December 2019

|

by: ante

|

Categories: Allgemein, Press Releases, 2019

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close